Addendum
Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42
Report documents
-
Addendum
Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42
Dossier assessment
Indication:
| Adults with ALK-positive advanced NSCLC who have not been previously treated with an ALK inhibitor |
Result of dossier assessment:
| Conclusion of dossier assessment A20-42 unchanged |
Additional information
Federal Joint Committee (G-BA)
15.10.2020 A G-BA decision was published.
Project details
- Project no.
- A20-85
- Commission
- Commission awarded on 08.09.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed